HUMASIS CO. LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,767 KRW | +0.28% |
|
-1.28% | -6.31% |
| Mar. 18 | Humasis Co. Ltd. announces an Equity Buyback for 17,533,607 shares. | CI |
| Mar. 18 | Humasis Co. Ltd. authorizes a Buyback Plan. | CI |
| Sales 2022 | 471B 342M | Sales 2023 | 13.83B 10.04M | Capitalization | 240B 174M |
|---|---|---|---|---|---|
| Net income 2022 | 183B 133M | Net income 2023 | -55.42B -40.24M | EV / Sales 2022 | 0.3 x |
| Net cash position 2022 | 316B 229M | Net cash position 2023 | 243B 176M | EV / Sales 2023 | -0.21 x |
| P/E ratio 2022 |
2.55
x | P/E ratio 2023 |
-4.33
x | Employees | 175 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 84.95% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.28% | ||
| 1 week | -1.28% | ||
| Current month | -13.80% | ||
| 1 month | -16.65% | ||
| 3 months | -3.81% | ||
| 6 months | -16.65% | ||
| Current year | -6.31% |
1 week
1 743.00
1 808.00
1 month
1 743.002 180.00
Current year
1 622.002 195.00
1 year
1 622.003 470.00
3 years
1 622.009 112.50
5 years
285.009 112.50
10 years
285.009 112.50
| Managers | Title | Age | Since |
|---|---|---|---|
Chung-Hak Cha
CEO | Chief Executive Officer | 59 | 17-09-27 |
Seung-Cheol Yoo
BRD | Director/Board Member | 60 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Seung-Cheol Yoo
BRD | Director/Board Member | 60 | - |
Chung-Hak Cha
CEO | Chief Executive Officer | 59 | 17-09-27 |
Seung-Woo Yoo
BRD | Director/Board Member | 56 | 17-09-27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 7 M€ | +0.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 1,767 | +0.28% | 465,695 |
| 24-04-23 | 1,762 | +0.06% | 372,708 |
| 24-04-22 | 1,761 | +0.11% | 474,110 |
| 24-04-19 | 1,759 | -2.17% | 862,986 |
| 24-04-18 | 1,798 | +0.45% | 772,865 |
End-of-day quote Korea S.E., April 23, 2024
More quotes
Humasis Co Ltd is a Korea-based company principally engaged in the manufacture and sale of in vitro diagnostic devices. The Company is engaged in the manufacture and sale of immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, cancer marker test devices and other products. In addition, the Company is engaged in the research and development of biomaterials and other products. The Company sells its products within domestic market and to overseas markets. The Company was established in 2000 and is located in Gunpo-si, Gyeonggi-do, South Korea.
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -6.31% | 163M | |
| -11.57% | 7.5B | |
| +2.98% | 5.48B | |
| +0.98% | 4.61B | |
| +5.18% | 4.47B | |
| -50.82% | 3.28B | |
| +11.23% | 2.71B | |
| -16.38% | 2.02B | |
| -2.66% | 1.69B | |
| -10.84% | 1.74B |
- Stock Market
- Equities
- A205470 Stock
